Sarcoma  >>  Tazverik (tazemetostat)  >>  Phase 1
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tazverik (tazemetostat) / Eisai, Ipsen
NCT02601937 / 2015-002468-18: A Phase 1 Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma

Hourglass Jun 2019 - Dec 2019 : From trial for pediatric patients with INI1-negative tumors or synovial sarcoma
Checkmark Completion of enrollment in P1 trial in pediatric patients with INI1-negative tumors
May 2018 - May 2018: Completion of enrollment in P1 trial in pediatric patients with INI1-negative tumors
Checkmark Initiation of dose expansion in P1 trial in pediatric patients with INI1-negative tumors or synovial sarcoma
Jan 2017 - Dec 2017: Initiation of dose expansion in P1 trial in pediatric patients with INI1-negative tumors or synovial sarcoma
More
Completed
1
109
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, E7438
Epizyme, Inc.
Rhabdoid Tumors, INI1-negative Tumors, Synovial Sarcoma, Malignant Rhabdoid Tumor of Ovary
10/21
10/21
NCT04537715: Study to Describe the Interaction Between Tazemetostat and Itraconazole and Between Tazemetostat and Rifampin in Participants With Advanced Cancer

Completed
1
42
Europe, US
Tazemetostat, EPZ-6438, Tazverik, Itraconazole, Sporanox, Rifampin, RIF, Rifampicin, Rifadin, Rimactane
Epizyme, Inc.
All Malignancies, Advanced Malignancies, Hematologic Malignancy, Solid Tumor, Follicular Lymphoma (FL), Non-Hodgkin Lymphoma (NHL), Diffuse Large B-Cell Lymphoma (DLBCL), Epithelioid Sarcoma (ES), Synovial Sarcoma, Renal Medullary Carcinoma, Mesothelioma, Rhabdoid Tumor
04/23
04/23

Download Options